TACI anticorps (PE/Dazzle™ 594)
-
- Antigène Voir toutes TACI (TNFRSF13B) Anticorps
- TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))
-
Reactivité
- Humain
-
Hôte
- Rat
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp TACI est conjugé à/à la PE/Dazzle™ 594
-
Application
- Flow Cytometry (FACS)
- Purification
- The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™ 594 under optimal conditions. The solution is free of unconjugated PE/Dazzle™ 594 and unconjugated antibody.
- Clone
- 1A1
- Isotype
- IgG2a kappa
- Top Product
- Discover our top product TNFRSF13B Anticorps primaire
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Protect from prolonged exposure to light. Do not freeze.
- Stock
- 4 °C
- Stockage commentaire
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- Antigène
- TACI (TNFRSF13B) (Tumor Necrosis Factor Receptor Superfamily, Member 13B (TNFRSF13B))
- Autre désignation
- CD267 (TNFRSF13B Produits)
- Synonymes
- anticorps CD267, anticorps CVID, anticorps CVID2, anticorps RYZN, anticorps TACI, anticorps TNFRSF14B, anticorps TNFRSF13B, anticorps 1200009E08Rik, anticorps Taci, anticorps TNF receptor superfamily member 13B, anticorps tumor necrosis factor receptor superfamily, member 13b, anticorps TNFRSF13B, anticorps Tnfrsf13b
- Sujet
- TACI, Transmembrane Activator CAML (calcium modulator and cyclophilin ligand) Interactor, is a 32 kD type III transmembrane protein. It belongs to TNF receptor superfamily, known as TNFRSF member 13B (TNFRSF13B) or CD267. TACI is expressed on B cells, and myeloma cells. TACI contains 2 cysteine-rich domains (CRDs). Recent studies, however, have shown that another shorter form (TACI_d2) of TACI exists wherein the N-terminal CRD is removed by alternative splicing. TACI_d2 contains full affinity for its ligands. Several proteins (BAFF/BLys, APRIL, Syndecan-2) have been identified as TACI ligands. The interaction of TACI with its ligands induces activation of the transcription factors NFAT, AP1, and NF-κ B and plays a crucial role in humoral immunity by negative regulation of B cell proliferation and survival.
-